Jump to navigation

  • Contact us
  • Data catalog (GHDx)
  • Research library
Home
Main menu
  • Home
  • Research and analysis
    • Global Burden of Disease (GBD)
    • Health policy and planning
    • Health by location
    • Health risks and issues
    • Diseases and conditions
    • Training on our research
    • Research and news library
  • Data tools and practices
    • Interactive data visuals
    • Data sources
    • How we collect data
    • Data practices
    • Verbal autopsy tool
    • Training on tools
    • Data for the private sector
  • News and events
    • News media
    • Blogs
    • Events
    • Media contacts
  • About us
    • Mission and vision
    • Diversity, Equity, and Inclusion
    • Our people
    • Awards
    • Careers
    • History
    • Governance
    • Contact us

Explore section

Research & Analysis

  • Global Burden of Disease (GBD)
  • Health policy and planning
  • Health by location
  • Health risks and issues
  • Diseases and conditions
  • Training on our research
  • Research and news library

Acute glomerulonephritis — Level 3 cause


Summary 722 000 cases (95% UI 595 000–878 000) of acute glomerulonephritis occurred in 2019, resulting in 10 500 deaths (7200–12 200) and 307 000 global DALYs (204 000–363 000).

Definition This Level 3 cause incorporates death and disability resulting from acute episodes of inflammation and injury to the filtering units of the kidney (glomeruli), generally resulting in haematuria, oedema, and hypertension.

Total sources
Incidence 285
Prevalence 0
Remission 0
Causes of death 2841
Other 0
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •To improve case ascertainment of acute glomerulonephritis, we used hospital and claims data that were adjusted to account for both inpatient and outpatient encounters, rather than inpatient encounters only.
  • •Tested new bias adjustment methods with the reference case definition based on published serological, histological, and/or imaging criteria. However, due to insufficient comparison data that is available, we used diagnosis as indicated by ICD code from hospital and claims data as reference.
  • •USA claims data were adjusted to other administrative sources using MR-BRT analysis prior to analysis in DisMod-MR, accounting for selection bias among privately insured populations.
  • •Modelled excess mortality rate (EMR) in MR-BRT by age and sex as a function of HAQ Index to provide greater guidance to DisMod-MR on expected pattern of EMR.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
0·0484
(0·0394
to 0·0583)
0·6
(0·5
to 0·8)
0·722
(0·595
to 0·878)
9·5
(7·7
to 11·5)
0·0105
(0·00720
to 0·0122)
0·1
(0·1
to 0·2)
0·305
(0·201
to 0·359)
3·9
(2·5
to 4·6)
0·00245
(0·00145
to 0·00380)
0·0
(0·0
to 0·0)
0·307
(0·204
to 0·363)
3·9
(2·6
to 4·6)
Females
0·0226
(0·0183
to 0·0273)
0·6
(0·5
to 0·7)
0·337
(0·277
to 0·411)
8·9
(7·2
to 10·9)
0·00485
(0·00378
to 0·00598)
0·1
(0·1
to 0·1)
0·137
(0·0938
to 0·177)
3·4
(2·3
to 4·5)
0·00114
(0·000683
to 0·00177)
0·0
(0·0
to 0·0)
0·139
(0·0948
to 0·178)
3·5
(2·3
to 4·5)
Males
0·0258
(0·0210
to 0·0310)
0·7
(0·5
to 0·8)
0·385
(0·318
to 0·467)
10·0
(8·2
to 12·2)
0·00567
(0·00297
to 0·00685)
0·2
(0·1
to 0·2)
0·168
(0·0828
to 0·206)
4·4
(2·1
to 5·3)
0·00131
(0·000773
to 0·00202)
0·0
(0·0
to 0·1)
0·169
(0·0841
to 0·208)
4·4
(2·2
to 5·4)
Percentage change 2010-19
Both Sexes
8·2%
(5·6
to 10·9)
–1·7%
(–3·8
to 0·2)
8·9%
(7·0
to 10·9)
–1·2%
(–2·7
to –0·1)
–2·2%
(–13·6
to 10·4)
–20·7%
(–29·7
to –10·6)
–17·0%
(–26·4
to –5·8)
–28·7%
(–36·7
to –19·3)
8·2%
(5·6
to 10·9)
–1·7%
(–3·8
to 0·2)
–16·8%
(–26·2
to –5·8)
–28·5%
(–36·5
to –19·2)
Females
8·4%
(5·5
to 10·9)
–1·6%
(–3·9
to 0·3)
9·0%
(7·0
to 11·0)
–1·1%
(–2·5
to 0·0)
–1·9%
(–16·0
to 13·7)
–21·2%
(–32·6
to –8·8)
–18·8%
(–29·9
to –5·3)
–30·4%
(–39·7
to –19·7)
8·4%
(5·5
to 10·9)
–1·6%
(–3·9
to 0·3)
–18·6%
(–29·7
to –5·2)
–30·3%
(–39·5
to –19·6)
Males
8·1%
(5·4
to 11·3)
–1·8%
(–4·2
to 0·7)
8·7%
(6·7
to 10·8)
–1·3%
(–3·1
to –0·1)
–2·5%
(–19·4
to 15·3)
–20·4%
(–34·3
to –6·4)
–15·5%
(–29·2
to –0·9)
–27·2%
(–39·2
to –15·0)
8·1%
(5·4
to 11·3)
–1·8%
(–4·2
to 0·7)
–15·3%
(–28·9
to –0·8)
–27·1%
(–38·9
to –15·0)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 115th 109th 161st 150th
2010 117th 119th 160th 160th
2019 115th 120th 158th 159th
Table 3: Rank among Level 3 causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by YLLs and YLDs for both sexes combined, 2019
No Legend
Figure 2: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 3: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 4: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019

Research & Analysis

  • Global Burden of Disease (GBD)
  • Health policy and planning
  • Health by location
  • Health risks and issues
  • Diseases and conditions
  • Training on our research
  • Research and news library

Stay connected

    

Sign up for our newsletter

  • Contact us
  • Donate
  • Privacy policy

© 2023

         Home to Highly Cited Researchers 2022, Clarivate

  • Home
  • Research and analysis
    • Global Burden of Disease (GBD)
    • Health policy and planning
    • Health by location
    • Health risks and issues
    • Diseases and conditions
    • Training on our research
    • Research and news library
  • Data tools and practices
    • Interactive data visuals
    • Data sources
    • How we collect data
    • Data practices
    • Verbal autopsy tool
    • Training on tools
    • Data for the private sector
  • News and events
    • News media
    • Blogs
    • Events
    • Media contacts
  • About us
    • Mission and vision
    • Diversity, Equity, and Inclusion
    • Our people
    • Awards
    • Careers
    • History
    • Governance
    • Contact us